Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry
Authors:
- for the EARLY Registry GroupFGfor the EARLY Registry Group
- Anselm K. GittAGAnselm K. Gitt
- Peter BramlagePBPeter Bramlage
- Sebastian A. PotthoffSPSebastian A. Potthoff
- Peter BaumgartPBPeter Baumgart
- Felix MahfoudFMFelix Mahfoud
- Hartmut BuhckHBHartmut Buhck
- Martina EhmenMEMartina Ehmen
- Taoufik OuarrakTOTaoufik Ouarrak
- Jochen SengesJSJochen Senges
- Roland E. SchmiederRSRoland E. Schmieder
Open Access
- 8 March 2016
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 16 (1) , 1-10
Abstract
Azilsartan medoxomil (AZL-M), has been demonstrated to be more effective than the other sartans currently in use; however, there is insufficient information available comparing it with ACE-inhibitors. Therefore, we aimed to compare the efficacy, safety, and tolerability of AZL-M with that of ACE-inhibitors in a real life clinical setting. The EARLY registry is a prospective, observational, national, multicentre registry with a follow-up period of 12 months. There were two principal objectives: 1) documentation of the achievement of target BP values set according to recent national and international guidelines, and 2) description of the safety profile of AZL-M. A total of 3 849 patients with essential arterial hypertension were recruited from primary care offices in Germany. Patients who initiated monotherapy at baseline comprising either AZL-M or an ACE-inhibitor were included at a ratio of seven to three. Results demonstrated that a blood pressure target of <140/90 mmHg was achieved by a significantly greater proportion of patients in the AZL-M group (61.1 %) compared with the ACE-inhibitor group (56.4 %; p < 0.05; OR, 1.21; 95 % CI, 1.03–1.42), with this finding maintained after adjusting for differences in baseline characteristics. AZL-M appeared to have an equivalent safety profile to the ACE-inhibitors, with a similar incidence of adverse events in the two patient groups (p = 0.73). These data add to the results of previous randomized controlled clinical trials suggesting that, compared with other agents that target the renin–angiotensin system, AZL-M provides statistically significant albeit small improvements in blood pressure control.Keywords
Funding Information
- Takeda Pharmaceuticals North America (US)
This publication has 29 references indexed in Scilit:
- EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registryBMC Cardiovascular Disorders, 2013
- Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramiprilJournal of Human Hypertension, 2013
- Critical evaluation of the efficacy and tolerability of azilsartanVascular Health and Risk Management, 2012
- Differential pharmacology and benefit/risk of azilsartan compared to other sartansVascular Health and Risk Management, 2012
- Retrospective Analysis of Real-World Efficacy of Angiotensin Receptor Blockers Versus Other Classes of Antihypertensive Agents in Blood Pressure ManagementClinical Therapeutics, 2011
- The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood PressureThe Journal of Clinical Hypertension, 2011
- RamiprilAmerican Journal of Cardiovascular Drugs, 2006
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- High prevalence and poor control of hypertension in primary careJournal Of Hypertension, 2004
- Valsartan: Long Term Efficacy and Tolerability Compared to Lisinopril in Elderly Patients with Essential HypertensionClinical and Experimental Hypertension, 1997